CA2491733A1 - Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders - Google Patents
Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders Download PDFInfo
- Publication number
- CA2491733A1 CA2491733A1 CA002491733A CA2491733A CA2491733A1 CA 2491733 A1 CA2491733 A1 CA 2491733A1 CA 002491733 A CA002491733 A CA 002491733A CA 2491733 A CA2491733 A CA 2491733A CA 2491733 A1 CA2491733 A1 CA 2491733A1
- Authority
- CA
- Canada
- Prior art keywords
- benzofuran
- dihydro
- carboxylic acid
- chloro
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39952002P | 2002-07-30 | 2002-07-30 | |
| US60/399,520 | 2002-07-30 | ||
| PCT/US2003/023430 WO2004010936A2 (en) | 2002-07-30 | 2003-07-25 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2491733A1 true CA2491733A1 (en) | 2004-02-05 |
Family
ID=31188592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002491733A Abandoned CA2491733A1 (en) | 2002-07-30 | 2003-07-25 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Country Status (8)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524882B2 (en) | 2002-07-30 | 2009-04-28 | Merck & Co., Inc. | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| DE602004009295T2 (de) | 2003-01-14 | 2008-07-03 | Arena Pharmaceuticals, Inc., San Diego | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| CA2532971A1 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| AU2003267347A1 (en) * | 2003-09-10 | 2005-03-29 | Galapagos Genomics N.V. | Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell |
| GB0403148D0 (en) * | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
| CN101014595A (zh) * | 2004-08-11 | 2007-08-08 | 杏林制药株式会社 | 新型环状氨基苯甲酸衍生物 |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| KR20070116644A (ko) * | 2005-03-23 | 2007-12-10 | 교린 세이야꾸 가부시키 가이샤 | 신규 환상 아미노페닐알칸산 유도체 |
| EP2025674A1 (de) * | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JPWO2009087981A1 (ja) * | 2008-01-11 | 2011-05-26 | 株式会社Kri | 重合性化合物及びこの製造方法 |
| CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CN104968659A (zh) | 2013-02-06 | 2015-10-07 | 住友化学株式会社 | 稠合杂环化合物 |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| JP2020507611A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 原発性胆汁性胆管炎の治療のための化合物および方法 |
| CN108546245A (zh) * | 2018-05-22 | 2018-09-18 | 绍兴文理学院 | 一种抗增殖活性中间体ml-098的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4205080A (en) | 1977-07-21 | 1980-05-27 | Shell Oil Company | 2,3-Dihydro benzofuran carboxamides |
| US4213999A (en) | 1979-06-07 | 1980-07-22 | Shell Oil Company | Inhibition of lipogenesis |
| US4213998A (en) | 1979-06-07 | 1980-07-22 | Shell Oil Company | Inhibition of lipogenesis |
| EP0061800B1 (en) | 1981-03-24 | 1985-08-28 | FISONS plc | Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them |
| JPS61158976A (ja) | 1984-12-28 | 1986-07-18 | Shionogi & Co Ltd | ベンゾフランおよびベンゾチオフエン誘導体 |
| FR2645537B1 (fr) | 1989-04-05 | 1994-03-04 | Fabre Medicament Pierre | Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique |
| US5273999A (en) | 1991-09-10 | 1993-12-28 | Hoffmann-La Roche Inc. | Carboxylic acid leukotriene B4 antagonists |
| US5352690A (en) | 1992-07-01 | 1994-10-04 | Eli Lilly And Company | 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists |
| US5324743A (en) | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
| JP3187611B2 (ja) * | 1993-05-17 | 2001-07-11 | キヤノン株式会社 | 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置 |
| US5516917A (en) | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
| CA2427610A1 (en) | 2000-10-31 | 2002-08-08 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| US7524882B2 (en) * | 2002-07-30 | 2009-04-28 | Merck & Co., Inc. | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
-
2003
- 2003-07-25 US US10/522,259 patent/US7524882B2/en not_active Expired - Fee Related
- 2003-07-25 AU AU2003256842A patent/AU2003256842B8/en not_active Ceased
- 2003-07-25 JP JP2004524883A patent/JP4475406B2/ja not_active Expired - Lifetime
- 2003-07-25 EP EP03771907A patent/EP1539136B1/en not_active Expired - Lifetime
- 2003-07-25 CA CA002491733A patent/CA2491733A1/en not_active Abandoned
- 2003-07-25 AT AT03771907T patent/ATE400564T1/de not_active IP Right Cessation
- 2003-07-25 DE DE60322075T patent/DE60322075D1/de not_active Expired - Lifetime
- 2003-07-25 WO PCT/US2003/023430 patent/WO2004010936A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003256842A1 (en) | 2004-02-16 |
| WO2004010936A3 (en) | 2004-08-26 |
| JP4475406B2 (ja) | 2010-06-09 |
| WO2004010936A2 (en) | 2004-02-05 |
| JP2006500335A (ja) | 2006-01-05 |
| US20050228044A1 (en) | 2005-10-13 |
| US7524882B2 (en) | 2009-04-28 |
| EP1539136A2 (en) | 2005-06-15 |
| DE60322075D1 (de) | 2008-08-21 |
| AU2003256842B8 (en) | 2009-06-18 |
| ATE400564T1 (de) | 2008-07-15 |
| AU2003256842B2 (en) | 2009-02-19 |
| EP1539136B1 (en) | 2008-07-09 |
| EP1539136A4 (en) | 2006-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6713508B2 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
| US6645997B2 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
| US7297715B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| AU2003256842B8 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| AU2001292874A1 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
| AU2002248221A1 (en) | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders | |
| JP2004521124A (ja) | 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類 | |
| JP2004513076A (ja) | 糖尿病治療で有用なｎ−置換インドール類 | |
| CA2400021A1 (en) | Aryloxyacetic acids for diabetes and lipid disorders | |
| EP1796665B1 (en) | Compounds for the treatment of dyslipidemia and other lipid disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20121231 |